Peter S. Greenleaf

Previously, Mr. Greenleaf was Chief Executive Officer of Cerecor Inc. Prior to joining Cerecor, he served as Chairman and CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by Mallincrodt Pharmaceuticals for $1.2 billion. Prior to joining Sucampo Pharmaceuticals, Mr. Greenleaf held senior positions spanning commercial, corporate development and strategy functions at several pharmaceutical companies. Notably, he served as President of Medimmune LLC, the biologics arm of AstraZeneca, and President of Medimmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Mr. Greenleaf is currently a member of the Board of Directors of Eyetech Pharmaceuticals and was previously a member of the Board of Directors of the Biotechnology Industry Organization (BIO) serving on the Governing Boards of the Emerging Companies and Health Sectors. He earned his M.B.A from St. Joseph’s University and a B.S. from Western Connecticut University.